News | April 12, 2026
C4 Therapeutics and Roche launch bold push into next-generation cancer drug modality
The partnership aims to fuse antibody-drug conjugation (ADC) technology with targeted protein degradation
The partnership aims to fuse antibody-drug conjugation (ADC) technology with targeted protein degradation
The patent, titled “ALPHA-1062 for treating Traumatic Brain Injury,” strengthens Alpha Cognition’s existing portfolio supporting both ALPHA-1062 and ZUNVEYL
Biopharma companies face persistent hurdles in cell line development, including long timelines, low yields, and high failure rates for novel molecules
The acquisition aims to bolster Merck’s hematology portfolio with Terns’ lead oncology candidate, TERN-701
As part of the deal, Red Nucleus also gains indirect ownership of the company’s Indian arm
The JADE trial enrolled 164 U.S. patients who initially received three monthly doses of OLN324 or faricimab, followed by 12 weeks off treatment with retreatment allowed only if disease recurred
Rs 66 lakh acquisition will support DNA engineering and novel cell-gene therapy alternatives to conventional chemotherapy
Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
Broadens downstream purification portfolio with next-generation Protein A chromatography for scalable manufacturing
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
Subscribe To Our Newsletter & Stay Updated
